Pictet Asset Management
TSHA icon

Pictet Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Pictet Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9M Buy
2,770,701
+2,751,383
+14,243% +$16.3M 0.02% 544
2026
Q1 		$86.4K Hold
19,318
– – ﹤0.01% 2054
2025
Q4 		$106K Buy
+19,318
New +$93.8K ﹤0.01% 2012

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management's TSHA Position: Q2 2026 in Review

Pictet Asset Management increased its Taysha Gene Therapies (TSHA) stake by 14,243% in Q2 2026, buying an estimated $16.3M and bringing the position to 2,770,701 shares worth $18.9M. The position accounts for 0.02% of the portfolio, ranked #544.

Pictet Asset Management first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Pictet Asset Management held 2,770,701 shares of Taysha Gene Therapies worth $18.9M as of Q2 2026.
  • Pictet Asset Management bought 2,751,383 Taysha Gene Therapies shares in Q2 2026, an estimated $16.3M.
  • Taysha Gene Therapies made up 0.02% of Pictet Asset Management's portfolio in Q2 2026, its #544 holding.
  • Pictet Asset Management first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.